PRNewswire (Wed, 10-Jun 7:55 AM ET)
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
PRNewswire (Wed, 20-May 7:00 AM ET)
PRNewswire (Fri, 15-May 8:05 AM ET)
Market Chameleon (Fri, 24-Apr 5:52 AM ET)
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
PRNewswire (Fri, 24-Apr 8:00 AM ET)
PRNewswire (Mon, 6-Apr 7:00 AM ET)
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Scinai Immunotherapeutics Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol SCNI.
As of July 2, 2026, SCNI stock price was flat at $0.27 with 31,561 million shares trading.
SCNI has a beta of 2.47, meaning it tends to be more sensitive to market movements. SCNI has a correlation of 0.10 to the broad based SPY ETF.
SCNI has a market cap of $1.40 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that SCNI belongs to (by Net Assets): SPDW.
SCNI has underperformed the market in the last year with a price return of -88.1% while the SPY ETF gained +21.3%. SCNI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.9% and -15.9%, respectively, while the SPY returned +13.9% and -0.3%, respectively.
SCNI support price is $.25 and resistance is $.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SCNI shares will trade within this expected range on the day.
